Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024 /PRNewswire/ -- ...
As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...
(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...
The MarketWatch News Department was not involved in the creation of this content. -- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authorization is based on ...
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback